In the context of DS, EGCG primarily viewed as an inhibitor of DYRK1A, a dual-specificity kinase overexpressed in DS and linked to neurodevelopmental and cognitive deficits [262,263]. The gene discussed is DYRK1A; the disease is Dravet syndrome.